Status:

APPROVED_FOR_MARKETING

Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

Lead Sponsor:

Shionogi

Conditions:

Bacterial Infections

Eligibility:

All Genders

Brief Summary

Expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.

Eligibility Criteria

Inclusion

  • Hospitalized patients with serious Gram-negative bacterial infections and who have limited treatment options and are not eligible for a clinical trial.

Exclusion

    Key Trial Info

    Start Date :

    Trial Type :

    EXPANDED_ACCESS

    End Date :

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT03780140

    Last Update

    February 28 2020

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.